SLU-PP-332 Research Guide

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule first reported by Zuercher et al. at Saint Louis University (SLU) School of Medicine. It functions as a pan-agonist of the estrogen-related receptor (ERR) family, activating all three ERR subtypes: ERRα, ERRβ, and ERRγ.

Unlike estrogen receptors (ERα, ERβ), estrogen-related receptors are constitutively active transcription factors — they regulate gene expression without requiring a ligand in their unmodified state. SLU-PP-332 acts as an agonist by stabilizing the active conformation of these receptors, increasing their transcriptional output above basal levels.

ERR target genes heavily overlap with PGC-1α (the master regulator of mitochondrial biogenesis) target genes — which is why ERR agonism has emerged as an approach to pharmacologically replicate some of the gene expression changes that aerobic exercise induces.

SLU-PP-332 is classified as a small molecule research chemical, not a peptide in the classical sense, but is supplied by Rainbow Peptide alongside other metabolic research compounds For Research Use Only.

ERR Biology: The Receptor Family

The estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — members of the nuclear receptor superfamily with no identified endogenous hormonal ligand. They regulate transcription by binding ERREs (ERR response elements) in the promoters of target genes.

Key ERR target gene categories:

• Mitochondrial biogenesis: TFAM (mitochondrial transcription factor A), NRF1, NRF2 — driving mitochondrial DNA replication and organelle proliferation
• Oxidative phosphorylation: Subunits of ETC complexes I–V, cytochrome c, ATP synthase — increasing respiratory chain capacity
• Fatty acid oxidation: HADHA, ACADM, CPT1 — increasing the cell's capacity to oxidize fat as fuel
• TCA cycle enzymes: IDH3A, OGDH — enhancing mitochondrial substrate oxidation

This gene program closely mirrors the adaptation to endurance exercise training, explaining why ERR agonists are studied as exercise mimetics.

Exercise Mimetic Mechanism

"Exercise mimetics" are compounds that pharmacologically recapitulate some of the gene expression and metabolic changes induced by physical exercise, without the physical activity itself. The field is relevant to research on:

• Muscle-wasting diseases (sarcopenia, cachexia, DMD) where exercise capacity is impaired
• Heart failure, where exercise intolerance is a primary limitation
• Aging biology, where mitochondrial decline drives functional deterioration
• Fundamental metabolism research requiring controlled mitochondrial upregulation

SLU-PP-332 specifically mimics the gene expression component of endurance exercise adaptation — not the mechanical load-sensing pathways (mTOR, mechanical tension) that drive hypertrophy. It is therefore most relevant to oxidative capacity and mitochondrial biology research, not strength/hypertrophy models.

Published Mouse Study Data

The landmark SLU-PP-332 study (Zuercher et al., 2023, published in Journal of Pharmacology and Experimental Therapeutics and widely covered in science media) showed:

Endurance Performance

• Mice treated with SLU-PP-332 ran ~50% longer on treadmill endurance tests compared to untreated controls following the same training protocol
• The increase was attributed to improved metabolic efficiency — not increased muscle mass (no difference in body weight or lean mass between groups)

Skeletal Muscle Gene Expression

• Significant upregulation of PGC-1α, NRF1, TFAM — mitochondrial biogenesis markers
• Increased expression of fatty acid oxidation genes (CPT1, HADHA)
• Higher mitochondrial content measured by citrate synthase activity and mtDNA:nDNA ratio

Metabolic Effects

• Increased fat oxidation measured by respiratory quotient (RQ) reduction during treadmill exercise
• No significant effects on body weight, food intake, or fasting blood glucose in normal mice

Cardiac Function Research

Cardiac muscle is one of the most mitochondria-rich tissues in the body — making ERR agonism highly relevant to cardiac research:

• In pressure overload (TAC) heart failure mouse models, SLU-PP-332 treatment attenuated cardiac fibrosis and preserved ejection fraction compared to vehicle-treated controls
• ERRα and ERRγ are highly expressed in cardiomyocytes; their transcriptional activity declines in failing hearts — a state of "mitochondrial insufficiency" that SLU-PP-332 is proposed to reverse
• The cardiac data positions SLU-PP-332 as potentially relevant to heart failure with reduced ejection fraction (HFrEF) research — an area where mitochondrial dysfunction is considered central to disease progression

Exercise Mimetics Comparison

SLU-PP-332's ERR agonism mechanism is distinct from AICAR (AMPK) and GW1516 (PPARδ), making it complementary in multi-compound research designs targeting different nodes of the exercise adaptation pathway.